FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of February 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F [ X ] Form 40 - F [ ]
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes [ ] No [ X ]
This Form 6-K consists of:
A press release issued by Vasogen Inc. on February 3, 2000, titled: "Vasogen
Appoints Prominent U.S. Cardiologist and Regulatory Affairs Expert to its
Scientific Advisory Board"
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By /s/Christopher Waddick
----------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: February 3, 2000
<PAGE>
Vasogen Inc. INVESTOR CONTACT
2155 Dunwin Drive, Suite 10 Trevor Burns
Mississauga, ON, Canada L5L 4M1 Investor Relations
tel (905) 569-2265 fax (905) 569-9231 tel (905) 569-9065
http://www.vasogen.com e-mail [email protected]
- --------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
Vasogen Appoints Prominent U.S. Cardiologist
and Regulatory Affairs Expert to its Scientific Advisory Board
Toronto, Ontario (February 3, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) is
pleased to announce the appointment of Dr. Craig Pratt to its Scientific
Advisory Board. Dr. Pratt is Professor of Medicine and Director of Clinical
Cardiovascular Research at Baylor College of Medicine, Houston, Texas.
Dr. Pratt is widely recognized for his knowledge of FDA regulatory procedures,
particularly in the area of cardiovascular disease. From 1987 to 1993, he was
Chair of the Cardiovascular and Renal Drugs Advisory Board of the U.S. Food and
Drug Administration. Since then, he has remained an active consultant to the FDA
Center for Drug Evaluation and Research. Dr. Pratt is also a leading authority
on the design and conduct of large multi-centre clinical trials in the field of
cardiology. He has acted as principal investigator or co-investigator for many
of the landmark trials that have led to fundamental changes in the management of
patients with heart disease. This includes numerous clinical trials sponsored by
the National Heart Lung and Blood Institute (NHLBI).
Dr. Pratt's interests span a wide spectrum of clinical areas in the field of
cardiovascular disease. He is the author of numerous publications and book
chapters and co-author of several cardiology textbooks. He reviews research
manuscripts for many of the leading heart journals, including American Journal
of Cardiology, Circulation, Journal of the American College of Cardiology as
well as studies submitted to The New England Journal of Medicine. In addition,
Dr. Pratt has consulted with most of the major pharmaceutical companies
regarding various aspects of clinical and regulatory drug development.
"Dr. Pratt's extensive expertise in regulatory affairs and the design,
management and interpretation of clinical trials in cardiovascular disease will
be a major asset to Vasogen," said Dr. Eldon Smith, Vasogen's Vice-President,
Scientific Affairs. "This is particularly important now that we are expanding
our U.S. clinical trials program to include a major new initiative in the area
of Congestive Heart Failure."
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases.
These therapies are designed to target fundamental disease-causing events,
providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
